Filtered By:
Cancer: HER2
This page shows you your search results in order of date.
Order by Relevance | Date
Total 260 results found since Jan 2013.
Inhibiting HER3 Hyperphosphorylation in HER2 ‐Overexpressing Breast Cancer through Multimodal Therapy with Branched Gold Nanoshells
A multimodal theranostic nanoplatform to treat breast cancer overexpressing the human epidermal growth factor receptors 2 (HER2) and 3 (HER3) is developed, and consisting of doxorubicin-loaded branched gold nanoshells functionalized with a small interfering RNA against HER3 and the HER2-specific antibody Trastuzumab able to simultaneously combine chemo- and photothermal, RNA silencing and immuno-therapies overcoming chemoresistance and reducing tumor size in vivo. AbstractTreatment failure in breast cancers overexpressing human epidermal growth factor receptor 2 (HER2) is associated mainly to the upregulation of human epid...
Source: Small - August 26, 2023 Category: Nanotechnology Authors: Eva Villar ‐Alvarez,
Irene Golán‐Cancela,
Alberto Pardo,
Brenda Velasco,
Javier Fernández‐Vega,
Adriana Cambón,
Abeer Al‐Modlej,
Antonio Topete,
Silvia Barbosa,
José A. Costoya,
Pablo Taboada Tags: Research Article Source Type: research
Budding uninhibited by benzimidazoles-1 (BUB1) regulates EGFR signaling by reducing EGFR internalization
Aging (Albany NY). 2023 Jul 3;15. doi: 10.18632/aging.204820. Online ahead of print.ABSTRACTEGFR signaling initiates upon ligand binding which leads to activation and internalization of the receptor-ligand complex. Here, we evaluated if BUB1 impacted EGFR signaling by regulating EGFR receptor internalization and activation. BUB1 was ablated genomically (siRNA) or biochemically (2OH-BNPP1) in cells. EGF ligand was used to initiate EGFR signaling while disuccinimidyl suberate (DSS) was used for cross linking cellular proteins. EGFR signaling was measured by western immunoblotting and receptor internalization was evaluated by...
Source: Aging - July 3, 2023 Category: Biomedical Science Authors: Shyam Nyati Grant Young Corey Speers Mukesh K Nyati Alnawaz Rehemtulla Source Type: research
Precision Therapy of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with a HER2/CD44‐Targeted Hydrogel Nanobot
Schematic illustration of the preparation of a HER2/CD44-targeted hydrogel nanobot (ALPR) by embedding the positively charged bio-responsive, liposome-encapsulated nanoparticles (LPR) formed by cationic liposome DOTAP/DOPE, survivin siRNA, andD-(KLAKLAK)2GGR16 (KLA-R16) into negatively charged Herceptin/hyaluronic acid cross-linked nanohydrogels (Herceptin-HA). AbstractHeterogeneity and drug resistance of tumor cells are the leading causes of incurability and poor survival for patients with recurrent breast cancer. In order to accurately deliver the biological anticancer drugs to different subtypes of malignant tumor cells...
Source: Small - May 8, 2023 Category: Nanotechnology Authors: Juan Chen,
Jinjin Li,
Xiaolu Sun,
Huixia Lu,
Kuai Liu,
Zhenbo Li,
Jianyue Guan,
Huiling Song,
Wei Wei,
Yanhong Ge,
Qiong Fan,
Wei Bao,
Buyong Ma,
Zixiu Du Tags: Research Article Source Type: research
S100A9 promotes glycolytic activity in HER2-positive breast cancer to induce immunosuppression in the tumour microenvironment
CONCLUSIONS: S100A9 overexpression upregulated the glycolysis activity of tumour cells through the c-Myc-related pathway, suppressing lymphocyte infiltration in the tumour stroma, affecting the efficacy of immune regulation and long-term survival of patients.PMID:36755606 | PMC:PMC9900376 | DOI:10.1016/j.heliyon.2023.e13294
Source: Cancer Control - February 9, 2023 Category: Cancer & Oncology Authors: Jia-Qi Yuan Shou-Man Wang Lei Guo Source Type: research
Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
CONCLUSIONS: Our results indicate that EDI3 may be a potential novel therapeutic target in patients with HER2-targeted therapy-resistant ER-HER2 + breast cancer that should be further explored.PMID:36670508 | DOI:10.1186/s13046-022-02578-w
Source: Clinical Genitourinary Cancer - January 20, 2023 Category: Cancer & Oncology Authors: Magdalena Keller Katharina Rohlf Annika Glotzbach Gregor Leonhardt Simon L üke Katharina Derksen Özlem Demirci Defne G öçener Mohammad AlWahsh J örg Lambert Cecilia Lindskog Marcus Schmidt Walburgis Brenner Matthias Baumann Eldar Zent Mia-Lisa Zischi Source Type: research
Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells
In conclusion, a combination of anti-Survivin siRNA and DOX would be a good alternative in HER2+ breast cancer therapy.PMID:36432729 | DOI:10.3390/pharmaceutics14112537
Source: Cancer Control - November 26, 2022 Category: Cancer & Oncology Authors: Sahar Eljack Emilie Allard-Vannier Yoann Misericordia Katel Herv é-Aubert Nicolas Aubrey Igor Chourpa Areeg Faggad Stephanie David Source Type: research
Overcoming the non-kinetic activity of EGFR1 using multi-functionalized mesoporous silica nanocarrier for in vitro delivery of siRNA
Sci Rep. 2022 Oct 14;12(1):17208. doi: 10.1038/s41598-022-21601-w.ABSTRACTTriple-negative breast cancer (TNBC) does not respond to HER2-targeted and hormone-based medicines. Epidermal growth factor receptor 1 (EGFR1) is commonly overexpressed in up to 70% of TNBC cases, so targeting cancer cells via this receptor could emerge as a favored modality for TNBC therapy due to its target specificity. The development of mesoporous silica nanoparticles (MSNs) as carriers for siRNAs remains a rapidly growing area of research. For this purpose, a multi-functionalized KIT-6 containing the guanidinium ionic liquid (GuIL), PEI and PEGy...
Source: Cancer Control - October 14, 2022 Category: Cancer & Oncology Authors: Javad Parnian Leila Ma'mani Mohamad Reza Bakhtiari Maliheh Safavi Source Type: research
Cancers, Vol. 14, Pages 4496: Ceramide Kinase (CERK) Emerges as a Common Therapeutic Target for Triple Positive and Triple Negative Breast Cancer Cells
jjaini Dasgupta
Sphingolipids are key signaling biomolecules that play a distinct role in cell proliferation, migration, invasion, drug resistance, metastasis, and apoptosis. Triple-negative (ER-PR-HER2-) and triple-positive (ER+PR+HER2+) breast cancer (called TNBC and TPBC, respectively) subtypes reveal distinct phenotypic characteristics and responses to therapy. Here, we present the sphingolipid profiles of BT-474 and MDA-MB-231 breast cancer cell lines representing the TPBC and TNBC subtypes. We correlated the level of different classes of sphingolipids and the expression of their corresponding metabolizing enzymes...
Source: Cancers - September 16, 2022 Category: Cancer & Oncology Authors: Kajal Rajput Mohammad Nafees Ansari Somesh K. Jha Trishna Pani Nihal Medatwal Somdeb Chattopadhyay Avinash Bajaj Ujjaini Dasgupta Tags: Article Source Type: research
PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations
We examined three HER2-positive, ER-negative breast cancer cell lines to determine the efficacy of a novel alpha isoform-specific PI3K inhibitor in combination with trastuzumab. The results indicated that this combination was effective in PIK3CA-mutant or PTEN-deficient breast cancer cells by inducing apoptosis and inhibiting the expression of downstream proteins. PTEN loss by siRNA modulation in parental HER2-positive cancer cells with PI3K signaling pathway alterations could not confer resistance to alpelisib or GDC-0077 plus trastuzumab. We selected the CK-MB-1 cell line without alterations in the PI3K pathway to demons...
Source: Cell Research - August 15, 2022 Category: Cytology Authors: Wei-Pang Chung Wei-Lun Huang Chun-Hui Lee Hui-Ping Hsu Wan-Ling Huang You-Yu Liu Wu-Chou Su Source Type: research
Efp promotes growth of triple-negative breast cancer cells
Biochem Biophys Res Commun. 2022 Jul 30;624:81-88. doi: 10.1016/j.bbrc.2022.07.071. Online ahead of print.ABSTRACTTriple-negative breast cancer (TNBC) is characterized by its high ability of invasiveness and metastasis, namely lacking expression of estrogen receptor (ER), progesterone receptor, and HER2. We previously demonstrated that estrogen responsive finger protein (Efp) plays a tumor-promotive role in ER-positive breast cancer, yet it remains to be addressed whether Efp contributes to TNBC pathophysiology. We here found that Efp mRNA and protein were abundantly expressed in TNBC patient-derived cells and MDA-MB-231 c...
Source: Cell Research - August 8, 2022 Category: Cytology Authors: Wataru Sato Kazuhiro Ikeda Noriko Gotoh Satoshi Inoue Kuniko Horie Source Type: research
